We are currently completing a Phase 1a/b clinical trial in patients with advanced or metastatic solid tumors. The Phase 1a portion investigated single agent activity with the Phase 1b in combination with nivolumab. Etigilimab is an anti-TIGIT therapeutic candidate designed to activate the immune system through multiple mechanisms and enable anti-tumor activity. TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is an inhibitory receptor that is thought to prevent T-cells from attacking tumor cells, similar to the inhibitory protein PD-1.
Information on our anti-TIGIT clinical program is available here: MPH-313 ClinicalTrials.gov.
PUBLIC PRESENTATIONS OF DATA FROM OUR ANTI-TIGIT PROGRAM INCLUDE:
- Initial results from a phase 1a/b study of etigilimab (MPH-313), an anti-T cell immunoreceptor with Ig and ITIM domains (TIGIT) antibody, in advanced solid tumors -SITC 2018
- Anti-TIGIT biomarker study: Inhibition of TIGIT induces loss of T regs from tumors and requires effector function for tumor growth inhibition - AACR 2018
- Pharmacodynamic biomarkers for anti-TIGIT treatment and prevalence of TIGIT expression in multiple solid tumor types - AACR 2017
- Anti-TIGIT induces T cell-mediated anti-tumor immune responses and combines with immune checkpoint inhibitors to enhance strong and long term anti-tumor immunity-AACR 2017
- Antibody against T cell Immunoreceptor with Ig and ITIM domains (TIGIT) Induces anti-Tumor Immune Response and Generates Long-Term Immune Memory - AACR 2017
- Interim biomarker analysis etigilimab MPH-313 anti-TIGIT antibody advanced solid tumors supports TIGIT associated MOA Keystone 2019
- Mereo’s Etigilimab antibody program featured in Nature Biotechnology review of TIGIT-targeting’s potential to be the next validated cancer checkpoint: Dolgin, E. Antibody engineers seek optimal drug targeting TIGIT checkpoint. Nat Biotechnol 38, 1007–1009 (2020)